Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

Biotechnology

Healthcare
$9.07 -1.39%

-$0.26 today

Market cap
$775.03M
Beta
1.60
P/E (TTM)
-9.1
EPS (TTM)
-$1.98
52W Low $4.12High $25.77

Volume 1.26M

Average 1.02M

GLUE Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Monte Rosa Therapeutics, Inc.NASDAQ: GLUE

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization dips below year-ago levels

Q1 FY2026 depreciation & amortization of $2.03M fell 0.9% year over year, behind the +0.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 2.8% from the prior quarter. Over 3 fiscal years it compounded at +30.7% a year.

Context

  • Depreciation & amortization amounted to 6.8% of revenue in FY2025, down 4.0 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -0.9% toward the trailing-twelve-month pace of +0.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.03M-2.8% QoQ
Last fiscal yearDec 2025
$8.36M+2.9% YoY
LTMMar 2026
$8.34M+0.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.9%——
1 year+2.9%——
3-year CAGR+30.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
8.36M USD
Year-over-year change
+2.9%
4-year CAGR
+40.7%

Depreciation & Amortization vs competitors

How GLUE compares with its peers on the latest reported figures

  • GLUE's LTM Mar 2026 depreciation & amortization of $8.34M is the 2nd largest of the 4 companies compared; the peer median is $5M.
  • Its year-over-year change of +0.8% is the 2nd highest of 4, against a peer median of -14.3%.
  • Depreciation & amortization amounts to 19.4% of revenue for GLUE, versus a peer median of 5.6%.
GLUE Competitors Peer median
Depreciation & Amortization for GLUE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$15.87M -14.3%+20.4%2.3%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$8.34M +0.8%+30.7%19.4%
ARVNArvinas, Inc.LTM Mar 2026$5M -19.4%-14.1%5.6%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$3.38M +84.9%+5.3%9.7%
Peer median (excluding GLUE) $5M-14.3%+5.3%5.6%

Competitors are the stored peer set for GLUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73.96M)(108.5M)(135.35M)(72.7M)(38.63M)
Depreciation & Amortization2.13M3.75M6.22M8.12M8.36M
Deferred Income Tax17K0000
Stock-Based Compensation5.2M11.66M16.67M18.13M18.87M
Change in Working Capital6.29M(2.13M)72.47M91.4M(9.19M)
Accounts Receivables0(187)1.9M332K(7M)
Inventory0187000
Accounts Payables(706K)(744K)5.76M6.25M(13.71M)
Other Working Capital6.99M(1.39M)64.81M84.81M11.52M
Other Non-Cash Items960K2.76M(3.81M)(2.95M)(2.2M)
Operating Cash Flow(59.36M)(92.47M)(43.8M)42M(22.8M)
Capital Expenditures(9.73M)(12.91M)(19.04M)(3.99M)(4.7M)
Acquisitions (Net)79K109K62K00
Purchases of Investments0(384.42M)(103.15M)(230.36M)(376.68M)
Sales of Investments0178M210.93M189.9M279.54M
Other Investing Activities00000
Investing Cash Flow(9.65M)(219.22M)88.8M(44.45M)(101.83M)
Debt Repayment00000
Common Stock Issued237.75M20.06M27.49M944K30.35M
Common Stock Repurchased000(641K)0
Dividends Paid00000
Other Financing Activities(3.19M)411K098.59M0
Financing Cash Flow377.56M20.47M27.49M98.89M30.35M
Effect of Forex Changes00000
Net Change in Cash308.55M(291.22M)72.49M96.44M(94.28M)
Free Cash Flow(69.1M)(105.38M)(62.84M)38.01M(27.5M)

Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

Intrinsic Alpha fair value

Locked

Current Price

$9.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.